drugset / Trial / NCT04604704
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
NaSingle-groupOpen-labelTreatment
Summary
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
Timeline
- Start
- 2021-01-28
- Primary completion
- 2023-01-23
- Completion
- 2023-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NAD+ | Unknown | 400 mg | Topical |
| Subject | Naltrexone | Small molecule | 4.5 mg | Oral |